xiaoniu2021 personal page - To The Moon

xiaoniu2021

xiaoniu2021

No personal profile

73Follow

1Followers

0Topic

0Badge

2021-06-08

Please like and comment for me

Sorry, the original content has been removed

2021-06-14

Pls comment and like with many thanks

Oracle, Adobe, Kroger, General Motors, and Other Stocks for Investors to Watch This Week

2021-06-22

Nice

Sorry, the original content has been removed

2021-06-12

Cool

Sorry, the original content has been removed

2021-06-07

Yea

Nio Begins Prepping For Nio Day 2021: What We Know So Far

2021-06-22

Like and comment. Thank you

Sorry, the original content has been removed

2021-06-17

Like and comment pls. Thanks ?

Sorry, the original content has been removed

2021-06-08

Nice

Opinion: Only ‘greedy’ drug companies will cure Alzheimer’s

2021-06-07

Hmm

Sorry, the original content has been removed

2021-06-07

Good

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582279635767115","uuid":"3582279635767115","gmtCreate":1619187349090,"gmtModify":1622772964080,"name":"xiaoniu2021","pinyin":"xiaoniu2021","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":73,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":144127981,"gmtCreate":1626272599843,"gmtModify":1703756867618,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Good night bro","listText":"Good night bro","text":"Good night bro","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/144127981","repostId":"144126462","repostType":1,"repost":{"id":144126462,"gmtCreate":1626272507556,"gmtModify":1703756857663,"author":{"id":"3571397064539484","authorId":"3571397064539484","name":"TheSavvyMind","avatar":"https://static.itradeup.com/news/90fa6b5b805291648a12010a2cc76211","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3571397064539484","idStr":"3571397064539484"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Time to sleep lol gd night all ??","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Time to sleep lol gd night all ??","text":"$AMC Entertainment(AMC)$Time to sleep lol gd night all ??","images":[{"img":"https://static.tigerbbs.com/5f51c54dc6d43d9c611bbc07ccb85dbf","width":"1284","height":"2457"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/144126462","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125407689,"gmtCreate":1624683557641,"gmtModify":1703843607532,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/125407689","repostId":"1108941456","repostType":4,"isVote":1,"tweetType":1,"viewCount":2181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128641808,"gmtCreate":1624515467904,"gmtModify":1703839030721,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Like.and comments pls","listText":"Like.and comments pls","text":"Like.and comments pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128641808","repostId":"2145012425","repostType":4,"repost":{"id":"2145012425","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624509732,"share":"https://ttm.financial/m/news/2145012425?lang=en_US&edition=fundamental","pubTime":"2021-06-24 12:42","market":"hk","language":"en","title":"HK-listed Agile climbs most in 5 weeks on theme park project with Melco","url":"https://stock-news.laohu8.com/highlight/detail?id=2145012425","media":"Reuters","summary":"** Shares of China's property developer Agile Group Holdings Ltd climb 2.4% to HK$10.36, the biggest","content":"<p>** Shares of China's property developer Agile Group Holdings Ltd climb 2.4% to HK$10.36, the biggest intraday percentage gain since May 18</p>\n<p>** Agile teams up a unit of Melco International Development&nbsp;to jointly develop mixed-use properties, including a theme park, on a piece of land in Zhongshan City in Guangdong province with aggregate investment of 6.05 bln yuan ($933.63 mln)</p>\n<p>** Shares of Melco gain 0.1% to HK$14.02, on track to snap two straight sessions of decline</p>\n<p>** The Hong Kong composite Industry Index tracking properties and construction stocks&nbsp;gains 0.6%</p>\n<p>** The Hang Seng China Enterprises Index slips 0.1% while the benchmark index&nbsp;climbs 0.02%</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Agile climbs most in 5 weeks on theme park project with Melco</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Agile climbs most in 5 weeks on theme park project with Melco\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-24 12:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of China's property developer Agile Group Holdings Ltd climb 2.4% to HK$10.36, the biggest intraday percentage gain since May 18</p>\n<p>** Agile teams up a unit of Melco International Development&nbsp;to jointly develop mixed-use properties, including a theme park, on a piece of land in Zhongshan City in Guangdong province with aggregate investment of 6.05 bln yuan ($933.63 mln)</p>\n<p>** Shares of Melco gain 0.1% to HK$14.02, on track to snap two straight sessions of decline</p>\n<p>** The Hong Kong composite Industry Index tracking properties and construction stocks&nbsp;gains 0.6%</p>\n<p>** The Hang Seng China Enterprises Index slips 0.1% while the benchmark index&nbsp;climbs 0.02%</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00200":"新濠国际发展","03383":"雅居乐集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145012425","content_text":"** Shares of China's property developer Agile Group Holdings Ltd climb 2.4% to HK$10.36, the biggest intraday percentage gain since May 18\n** Agile teams up a unit of Melco International Development to jointly develop mixed-use properties, including a theme park, on a piece of land in Zhongshan City in Guangdong province with aggregate investment of 6.05 bln yuan ($933.63 mln)\n** Shares of Melco gain 0.1% to HK$14.02, on track to snap two straight sessions of decline\n** The Hong Kong composite Industry Index tracking properties and construction stocks gains 0.6%\n** The Hang Seng China Enterprises Index slips 0.1% while the benchmark index climbs 0.02%","news_type":1,"symbols_score_info":{"03383":0.9,"00200":0.9}},"isVote":1,"tweetType":1,"viewCount":2419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129947356,"gmtCreate":1624354790375,"gmtModify":1703834229415,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Like and comment.&nbsp; Thank you","listText":"Like and comment.&nbsp; Thank you","text":"Like and comment. Thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129947356","repostId":"1186919064","repostType":4,"isVote":1,"tweetType":1,"viewCount":3122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120825133,"gmtCreate":1624319468622,"gmtModify":1703833212883,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/120825133","repostId":"1167650307","repostType":4,"isVote":1,"tweetType":1,"viewCount":3138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120330009,"gmtCreate":1624296497101,"gmtModify":1703832868432,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"The market pulled back after the latest Fed meeting on Wednesday, where policymakers signaled they expect to raise interest rates by late 2023, sooner than they had previously anticipated. The selloff intensified Friday after St. Louis Fed President James Bullard told CNBC he sees the Fed starting to raise interest rates in late 2022.Now is a time to be looking to add stocks to one's watchlist, but why do the stocks chosen above stand out? Before turning to that question, it is important to consider how one goes about choosing a stock in the first place. Superior fundamentals and technical action, and buying at the right time, are all part of a shrewd investing formula.","listText":"The market pulled back after the latest Fed meeting on Wednesday, where policymakers signaled they expect to raise interest rates by late 2023, sooner than they had previously anticipated. The selloff intensified Friday after St. Louis Fed President James Bullard told CNBC he sees the Fed starting to raise interest rates in late 2022.Now is a time to be looking to add stocks to one's watchlist, but why do the stocks chosen above stand out? Before turning to that question, it is important to consider how one goes about choosing a stock in the first place. Superior fundamentals and technical action, and buying at the right time, are all part of a shrewd investing formula.","text":"The market pulled back after the latest Fed meeting on Wednesday, where policymakers signaled they expect to raise interest rates by late 2023, sooner than they had previously anticipated. The selloff intensified Friday after St. Louis Fed President James Bullard told CNBC he sees the Fed starting to raise interest rates in late 2022.Now is a time to be looking to add stocks to one's watchlist, but why do the stocks chosen above stand out? Before turning to that question, it is important to consider how one goes about choosing a stock in the first place. Superior fundamentals and technical action, and buying at the right time, are all part of a shrewd investing formula.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120330009","repostId":"2145084835","repostType":4,"isVote":1,"tweetType":1,"viewCount":3543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162305518,"gmtCreate":1624033327334,"gmtModify":1703827310050,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Good say. Oil is back","listText":"Good say. Oil is back","text":"Good say. Oil is back","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162305518","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":2145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166895084,"gmtCreate":1624000341948,"gmtModify":1703826195788,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Pls like and comment.&nbsp; Thanks","listText":"Pls like and comment.&nbsp; Thanks","text":"Pls like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166895084","repostId":"1149669763","repostType":4,"isVote":1,"tweetType":1,"viewCount":2487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161037621,"gmtCreate":1623896069063,"gmtModify":1703822870601,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Like and comment pls. Thanks ?","listText":"Like and comment pls. Thanks ?","text":"Like and comment pls. Thanks ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161037621","repostId":"2144130887","repostType":4,"isVote":1,"tweetType":1,"viewCount":2978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185221565,"gmtCreate":1623654921057,"gmtModify":1704207913531,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Pls comment and like with many thanks","listText":"Pls comment and like with many thanks","text":"Pls comment and like with many thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/185221565","repostId":"1146430910","repostType":4,"repost":{"id":"1146430910","kind":"news","pubTimestamp":1623624483,"share":"https://ttm.financial/m/news/1146430910?lang=en_US&edition=fundamental","pubTime":"2021-06-14 06:48","market":"us","language":"en","title":"Oracle, Adobe, Kroger, General Motors, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1146430910","media":"Barrons","summary":"It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and","content":"<p>It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and Kroger on&nbsp;Thursday make up&nbsp;the notable reports over the coming days.</p>\n<p>Several other companies will speak with investors this week.&nbsp;Activision Blizzard and General Motors host their annual shareholder meetings on Monday, followed by Humana’s investor day on Tuesday and events by&nbsp;DXC Technology and NRG Energy on Thursday.</p>\n<p>The main event on the economic calendar this week will be the&nbsp;Federal Reserve’s rate-setting committee’s June meeting on Tuesday and Wednesday. The committee’s monetary-policy decision and a post-meeting press conference with Chairman&nbsp;Jerome Powell will be the focus of attention on Wednesday afternoon. Talk of inflation and bond-purchase tapering will be on the agenda.</p>\n<p>Data out this week include the Bureau of Labor Statistics’ producer price index for May and the Census Bureau’s retail-sales data for May, both on Tuesday, followed by the Conference Board’s Leading Economic Index for May on Thursday. There will also be data on the U.S. housing market out on Tuesday and Wednesday.</p>\n<p><b>Monday 6/14</b></p>\n<p>Roche Holding&nbsp;presents data on its spinal muscular atrophy drug, Evrysdi, at the 2021 CureSMA annual meeting.</p>\n<p>Activision Blizzard and General Motors hold their annual shareholder meetings.</p>\n<p><b>Tuesday 6/15</b></p>\n<p>Oracle announces fiscal fourth-quarter and full-year 2021 results.</p>\n<p>Humana hosts its biennial investor day virtually.</p>\n<p><b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for June. Economists forecast an 83 reading, matching the May figure. Home builders remain very bullish on the housing market but are concerned about the availability and cost of building materials.</p>\n<p><b>The Census Bureau</b>&nbsp;reports retail-sales data for May. Expectations are for a 0.5% month-over-month decline, following a flat April. Excluding autos, spending is seen rising 0.6%, compared with a 0.8% decrease previously.</p>\n<p><b>The Bureau of Labor</b>&nbsp;Statistics releases the producer price index for May. Consensus estimate is for a 0.4% monthly increase, with the core PPI, which excludes volatile food and energy prices, expected to rise 0.4% as well. This compares with gains of 0.6% and 0.7%, respectively, in April.</p>\n<p><b>Wednesday 6/16</b></p>\n<p><b>The FOMC announces</b>&nbsp;its monetary-policy decision. With the federal-funds rate all but certain to remain near zero, Wall Street is looking for clues as to when the Federal Reserve might scale back its bond purchases.</p>\n<p>Lennar reports quarterly results.</p>\n<p><b>The Census Bureau</b>&nbsp;reports new residential construction data for May. The economists forecast a seasonally adjusted annual rate of 1.63 million housing starts, slightly higher than April’s data. Housing starts are just below their post-financial-crisis peak of 1.73 million from March.</p>\n<p><b>Thursday 6/17</b></p>\n<p>Adobe and Kroger hold conference calls to discuss earnings.</p>\n<p>DXC Technology and NRG Energy hold their 2021 investor days.</p>\n<p><b>The Conference Board</b>&nbsp;releases its Leading Economic Index for May. The LEI is expected to rise 1.1% month over month to 114.5, after gaining 1.6% in April. The index has now surpassed its pre-Covid peak, set back in January of 2020. The Conference Board now projects 8% to 9% annualized gross-domestic-product growth for the second quarter, and 6.4% for the year.</p>\n<p><b>The Department of Labor</b>&nbsp;reports initial jobless claims for the week ending on June 15. Jobless claims this past week were 376,000, the lowest total since March of 2020.</p>\n<p><b>Friday 6/18</b></p>\n<p><b>The Bank of Japan</b>&nbsp;announces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at negative 0.1%. The BOJ recently updated its GDP forecast to 4% growth for fiscal 2021 and 2.4% for fiscal 2022.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oracle, Adobe, Kroger, General Motors, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOracle, Adobe, Kroger, General Motors, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 06:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/oracle-adobe-kroger-general-motors-and-other-stocks-for-investors-to-watch-this-week-51623610821?mod=hp_LEADSUPP_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and Kroger on Thursday make up the notable reports over the coming days.\nSeveral other companies will ...</p>\n\n<a href=\"https://www.barrons.com/articles/oracle-adobe-kroger-general-motors-and-other-stocks-for-investors-to-watch-this-week-51623610821?mod=hp_LEADSUPP_2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","GM":"通用汽车",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","KR":"克罗格","ADBE":"Adobe","ORCL":"甲骨文"},"source_url":"https://www.barrons.com/articles/oracle-adobe-kroger-general-motors-and-other-stocks-for-investors-to-watch-this-week-51623610821?mod=hp_LEADSUPP_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146430910","content_text":"It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and Kroger on Thursday make up the notable reports over the coming days.\nSeveral other companies will speak with investors this week. Activision Blizzard and General Motors host their annual shareholder meetings on Monday, followed by Humana’s investor day on Tuesday and events by DXC Technology and NRG Energy on Thursday.\nThe main event on the economic calendar this week will be the Federal Reserve’s rate-setting committee’s June meeting on Tuesday and Wednesday. The committee’s monetary-policy decision and a post-meeting press conference with Chairman Jerome Powell will be the focus of attention on Wednesday afternoon. Talk of inflation and bond-purchase tapering will be on the agenda.\nData out this week include the Bureau of Labor Statistics’ producer price index for May and the Census Bureau’s retail-sales data for May, both on Tuesday, followed by the Conference Board’s Leading Economic Index for May on Thursday. There will also be data on the U.S. housing market out on Tuesday and Wednesday.\nMonday 6/14\nRoche Holding presents data on its spinal muscular atrophy drug, Evrysdi, at the 2021 CureSMA annual meeting.\nActivision Blizzard and General Motors hold their annual shareholder meetings.\nTuesday 6/15\nOracle announces fiscal fourth-quarter and full-year 2021 results.\nHumana hosts its biennial investor day virtually.\nThe National Association of Home Builders releases its Housing Market Index for June. Economists forecast an 83 reading, matching the May figure. Home builders remain very bullish on the housing market but are concerned about the availability and cost of building materials.\nThe Census Bureau reports retail-sales data for May. Expectations are for a 0.5% month-over-month decline, following a flat April. Excluding autos, spending is seen rising 0.6%, compared with a 0.8% decrease previously.\nThe Bureau of Labor Statistics releases the producer price index for May. Consensus estimate is for a 0.4% monthly increase, with the core PPI, which excludes volatile food and energy prices, expected to rise 0.4% as well. This compares with gains of 0.6% and 0.7%, respectively, in April.\nWednesday 6/16\nThe FOMC announces its monetary-policy decision. With the federal-funds rate all but certain to remain near zero, Wall Street is looking for clues as to when the Federal Reserve might scale back its bond purchases.\nLennar reports quarterly results.\nThe Census Bureau reports new residential construction data for May. The economists forecast a seasonally adjusted annual rate of 1.63 million housing starts, slightly higher than April’s data. Housing starts are just below their post-financial-crisis peak of 1.73 million from March.\nThursday 6/17\nAdobe and Kroger hold conference calls to discuss earnings.\nDXC Technology and NRG Energy hold their 2021 investor days.\nThe Conference Board releases its Leading Economic Index for May. The LEI is expected to rise 1.1% month over month to 114.5, after gaining 1.6% in April. The index has now surpassed its pre-Covid peak, set back in January of 2020. The Conference Board now projects 8% to 9% annualized gross-domestic-product growth for the second quarter, and 6.4% for the year.\nThe Department of Labor reports initial jobless claims for the week ending on June 15. Jobless claims this past week were 376,000, the lowest total since March of 2020.\nFriday 6/18\nThe Bank of Japan announces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at negative 0.1%. The BOJ recently updated its GDP forecast to 4% growth for fiscal 2021 and 2.4% for fiscal 2022.","news_type":1,"symbols_score_info":{"KR":0.9,".DJI":0.9,".SPX":0.9,"ORCL":0.9,"GM":0.9,"ADBE":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":3508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185221809,"gmtCreate":1623654870901,"gmtModify":1704207910783,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185221809","repostId":"1165811803","repostType":4,"isVote":1,"tweetType":1,"viewCount":746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188293635,"gmtCreate":1623441824927,"gmtModify":1704203786171,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188293635","repostId":"2142572209","repostType":4,"isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183267572,"gmtCreate":1623333288296,"gmtModify":1704201129881,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Zhun bo","listText":"Zhun bo","text":"Zhun bo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183267572","repostId":"1128810191","repostType":4,"isVote":1,"tweetType":1,"viewCount":866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":180098584,"gmtCreate":1623163289348,"gmtModify":1704197479700,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Sad case for me&nbsp;","listText":"Sad case for me&nbsp;","text":"Sad case for me","images":[{"img":"https://static.tigerbbs.com/ddfa3fdd2e235373a5b97424619bef67","width":"1080","height":"2679"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180098584","isVote":1,"tweetType":1,"viewCount":856,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":117542129,"gmtCreate":1623154023161,"gmtModify":1704197167352,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Please like and comment for me","listText":"Please like and comment for me","text":"Please like and comment for me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/117542129","repostId":"1154765176","repostType":4,"isVote":1,"tweetType":1,"viewCount":1212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117546144,"gmtCreate":1623153945988,"gmtModify":1704197165897,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Yeah!!","listText":"Yeah!!","text":"Yeah!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117546144","repostId":"1111940861","repostType":4,"isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117543634,"gmtCreate":1623153771328,"gmtModify":1704197161475,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/117543634","repostId":"1127979401","repostType":4,"repost":{"id":"1127979401","kind":"news","pubTimestamp":1623153568,"share":"https://ttm.financial/m/news/1127979401?lang=en_US&edition=fundamental","pubTime":"2021-06-08 19:59","market":"us","language":"en","title":"Opinion: Only ‘greedy’ drug companies will cure Alzheimer’s","url":"https://stock-news.laohu8.com/highlight/detail?id=1127979401","media":"marketwatch","summary":"Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my ","content":"<p><img src=\"https://static.tigerbbs.com/783580e857537ceb68ca7c6330ee4132\" tg-width=\"1260\" tg-height=\"736\">Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my fellow members of the (ahem) “mainstream media.”</p>\n<p>Now that BiogenBIIB,+38.34%has got approval forits new Alzheimer’s drug—the first approved by the FDA in almost 20 years — how much should they be allowed to charge for it?</p>\n<p>What’s the ethically correct figure? What will exempt them from charges of “greed” or “gouging?” What is “too much?”</p>\n<p>The manufacturing cost per pill? The cost plus a small margin? What’s the number?</p>\n<p>I bring this up because few things matter as much for the lives of senior citizens in America—and seniors in the rest of the world—than the development of new drugs. I have personally seen up close how Alzheimer’s destroys people, sometimes as young as their 50s and 60s. This has included close members of my family.</p>\n<p>Some six million Americans already have this cruel, vicious and incurable disease, and ahorrific 50 million around the world. That’s 50 million death sentences. Ten million more get it every year.</p>\n<p>The drug industry developed five vaccines in one year for COVID-19, a disease associated with the deaths of 3.7 million people world-wide. Alzheimer’s treatments? Oh, one for every 20 years.</p>\n<p>Let’s be honest: Many people subconsciously shrug off this issue on the principle that Alzheimer’s will only happen to someone else. Alas, many of the people reading this article are going to get this disease. For many more, your father, mother, wife or husband will get it. Or a sibling or close friend. At which point, the “hey, maybe we should have made this a bigger national priority” argument will strike, but too late to help.</p>\n<p>This is the context worth bearing in mind when we hear about drugs getting approved—and, just as importantly, when we hear people demagoguing about “greedy” drug companies and “overpriced” drugs. It’s not just this new Alzheimer’s drug, either.</p>\n<p>If “drug” companies are making out like bandits, someone really has to explain to me why it doesn’t show up in the…er…stock prices. In the past decade, investors the iShares U.S. Pharmaceuticals exchange-traded fundIHE,+0.61%have made far lower returns than they could have done just by randomly picking a bunch of non-pharmaceutical stocks out of the newspaper. These companies have been worse investments than a simple S&amp;P 500SPX,-0.08%index fund like the SPDR S&amp;P 500 ETFSPY,-0.10%,or the Invesco S&amp;P 500 Equal Weight ETFRSP,-0.18%.</p>\n<p>Even Biogen itself had substantially underperformed the broader stock market index for a decade. Until Monday.</p>\n<p>No, the industry returns aren’t terrible. But they are hardly the giant free oil well that critics sometimes suggest. I checked out the data from Dartmouth College finance professor Kenneth French, who has tracked stock market returns by industry going back decades. Going all the way back to the 1920s, according to his numbers, the pharmaceuticals industry barely cracks the top one-third of all industries by stock returns. So far this millennium, the total returns from major pharmaceutical companies have been about a third less than those from the S&amp;P 500 index. Biotechs have done much better, but they were a much smaller sector. And even biotech has trailed the returns of alcohol and tobacco companies.</p>\n<p>How are we going to get billions of dollars more capital invested in curing Alzheimer’s and diabetes and cancer when investors can make more money investing in making booze and cigarettes? This is upside down.</p>\n<p>Meanwhile the regulation are all messed up and back to front as well.This headline says it all: “FDA Approves Alzheimer’s Drug Despite Fierce Debate Over&nbsp;Whether&nbsp;It Works.”</p>\n<p>This is nuts. Maybe the new treatment makes things better, maybe it doesn’t. Apparently people aren’t certain. It’s hardly a surprise: The treatment is new, and the disease is complicated. But the first question to ask isn’t whether it makes things better, but whether it makes things worse. The current situation is catastrophic for anyone with the disease. People are dying. Lives are being destroyed.</p>\n<p>Waiting to be sure treatment works would be like falling out of a plane with a parachute on, but hesitating to pull the cord because, well, it might not work. It suggests a basic misunderstanding of game theory. (Or common sense.)</p>\n<p>It’s one thing to hesitate about approving a new drug for a nonfatal illness. You don’t want to make people sicker, or cause needless suffering or death. But with this kind of illness that really doesn’t apply.</p>\n<p>Anyone who says “oh, no, we need to be really careful, and if need be delay these new treatments for years to make sure they are absolutely 100% safe” is speaking from a position of privilege. They should try saying that to someone watching a loved one be destroyed by the illness. It’s easy to play that card when it’s not happening to you, or someone you love.</p>\n<p>A look through the Biogen’s public filings tells the sorry story. This new&nbsp;Alzheimer’s&nbsp;treatment entered Phase 3 trials in 2015—six years ago. Did I mention it took one year to get COVID vaccines to market?</p>\n<p>Meanwhile, check out all the costs associated with developing this treatment. Biogen struck a collaboration deal with Eisai to work on this drug in 2014. Since then the two of them have spent a total of $1.1 billion on it. If it hadn’t been approved, that’s $1.1 billion down the drain.</p>\n<p>I want more of these treatments. And I want them quickly, not every two decades. I want trillions pouring into this industry. And I know that lower returns, and more bureaucracy, aren’t the way to get them.</p>\n<p>None of this, of course, means blind, passive or foolish naiveté about the drug industry or pricing. Drug manufacturers spend about $160 million a year on lobbying, and people involved in the business donated nearly $30 million a year to politicians running for office. Look through the proxy statements and you’ll see plenty of Big Pharma CEOs living off<i>the fatta the lan</i>(like lots of other CEOs).Yes, of course Medicare should have greater freedom to negotiate drug prices.</p>\n<p>Few people know more about malfeasance and greed in the drug industry than investigative journalist Gerald Posner, who literally wrote the book on it —Pharma: Greed, Lies, and the Poisoning Of America.</p>\n<p>“Most of the time I agree with your take,” he tells me. “FDA red tape bureaucracy is slow and costly and good R&amp;D can cost a fortune, all with no guarantee of success. So risk takers, i.e. drug companies, should be rewarded with financial incentives.”</p>\n<p>But, he adds, U.S. drug companies are already getting plenty of help. The U.S. has the longest patent protections of any major economy. He adds that big U.S. pharma companies get huge research support from taxpayers through the National Institute for Health.</p>\n<p>“From 2010 through 2016, every one of the 210 drugs approved for sale by the FDA were completely or in part funded by the NIH,” he says. The fund came to more than $100 billion, he adds.</p>\n<p>All good points. But I fear that as long as it’s more profitable to invest in cigarettes or booze than it is in curing Alzheimer’s, we will all be left with Plan B for our old age: Hoping and praying we don’t get Alzheimer’s.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opinion: Only ‘greedy’ drug companies will cure Alzheimer’s</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpinion: Only ‘greedy’ drug companies will cure Alzheimer’s\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/only-greedy-drug-companies-will-cure-alzheimers-11623152892?mod=newsviewer_click><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my fellow members of the (ahem) “mainstream media.”\nNow that BiogenBIIB,+38.34%has got approval forits ...</p>\n\n<a href=\"https://www.marketwatch.com/story/only-greedy-drug-companies-will-cure-alzheimers-11623152892?mod=newsviewer_click\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.marketwatch.com/story/only-greedy-drug-companies-will-cure-alzheimers-11623152892?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1127979401","content_text":"Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my fellow members of the (ahem) “mainstream media.”\nNow that BiogenBIIB,+38.34%has got approval forits new Alzheimer’s drug—the first approved by the FDA in almost 20 years — how much should they be allowed to charge for it?\nWhat’s the ethically correct figure? What will exempt them from charges of “greed” or “gouging?” What is “too much?”\nThe manufacturing cost per pill? The cost plus a small margin? What’s the number?\nI bring this up because few things matter as much for the lives of senior citizens in America—and seniors in the rest of the world—than the development of new drugs. I have personally seen up close how Alzheimer’s destroys people, sometimes as young as their 50s and 60s. This has included close members of my family.\nSome six million Americans already have this cruel, vicious and incurable disease, and ahorrific 50 million around the world. That’s 50 million death sentences. Ten million more get it every year.\nThe drug industry developed five vaccines in one year for COVID-19, a disease associated with the deaths of 3.7 million people world-wide. Alzheimer’s treatments? Oh, one for every 20 years.\nLet’s be honest: Many people subconsciously shrug off this issue on the principle that Alzheimer’s will only happen to someone else. Alas, many of the people reading this article are going to get this disease. For many more, your father, mother, wife or husband will get it. Or a sibling or close friend. At which point, the “hey, maybe we should have made this a bigger national priority” argument will strike, but too late to help.\nThis is the context worth bearing in mind when we hear about drugs getting approved—and, just as importantly, when we hear people demagoguing about “greedy” drug companies and “overpriced” drugs. It’s not just this new Alzheimer’s drug, either.\nIf “drug” companies are making out like bandits, someone really has to explain to me why it doesn’t show up in the…er…stock prices. In the past decade, investors the iShares U.S. Pharmaceuticals exchange-traded fundIHE,+0.61%have made far lower returns than they could have done just by randomly picking a bunch of non-pharmaceutical stocks out of the newspaper. These companies have been worse investments than a simple S&P 500SPX,-0.08%index fund like the SPDR S&P 500 ETFSPY,-0.10%,or the Invesco S&P 500 Equal Weight ETFRSP,-0.18%.\nEven Biogen itself had substantially underperformed the broader stock market index for a decade. Until Monday.\nNo, the industry returns aren’t terrible. But they are hardly the giant free oil well that critics sometimes suggest. I checked out the data from Dartmouth College finance professor Kenneth French, who has tracked stock market returns by industry going back decades. Going all the way back to the 1920s, according to his numbers, the pharmaceuticals industry barely cracks the top one-third of all industries by stock returns. So far this millennium, the total returns from major pharmaceutical companies have been about a third less than those from the S&P 500 index. Biotechs have done much better, but they were a much smaller sector. And even biotech has trailed the returns of alcohol and tobacco companies.\nHow are we going to get billions of dollars more capital invested in curing Alzheimer’s and diabetes and cancer when investors can make more money investing in making booze and cigarettes? This is upside down.\nMeanwhile the regulation are all messed up and back to front as well.This headline says it all: “FDA Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works.”\nThis is nuts. Maybe the new treatment makes things better, maybe it doesn’t. Apparently people aren’t certain. It’s hardly a surprise: The treatment is new, and the disease is complicated. But the first question to ask isn’t whether it makes things better, but whether it makes things worse. The current situation is catastrophic for anyone with the disease. People are dying. Lives are being destroyed.\nWaiting to be sure treatment works would be like falling out of a plane with a parachute on, but hesitating to pull the cord because, well, it might not work. It suggests a basic misunderstanding of game theory. (Or common sense.)\nIt’s one thing to hesitate about approving a new drug for a nonfatal illness. You don’t want to make people sicker, or cause needless suffering or death. But with this kind of illness that really doesn’t apply.\nAnyone who says “oh, no, we need to be really careful, and if need be delay these new treatments for years to make sure they are absolutely 100% safe” is speaking from a position of privilege. They should try saying that to someone watching a loved one be destroyed by the illness. It’s easy to play that card when it’s not happening to you, or someone you love.\nA look through the Biogen’s public filings tells the sorry story. This new Alzheimer’s treatment entered Phase 3 trials in 2015—six years ago. Did I mention it took one year to get COVID vaccines to market?\nMeanwhile, check out all the costs associated with developing this treatment. Biogen struck a collaboration deal with Eisai to work on this drug in 2014. Since then the two of them have spent a total of $1.1 billion on it. If it hadn’t been approved, that’s $1.1 billion down the drain.\nI want more of these treatments. And I want them quickly, not every two decades. I want trillions pouring into this industry. And I know that lower returns, and more bureaucracy, aren’t the way to get them.\nNone of this, of course, means blind, passive or foolish naiveté about the drug industry or pricing. Drug manufacturers spend about $160 million a year on lobbying, and people involved in the business donated nearly $30 million a year to politicians running for office. Look through the proxy statements and you’ll see plenty of Big Pharma CEOs living offthe fatta the lan(like lots of other CEOs).Yes, of course Medicare should have greater freedom to negotiate drug prices.\nFew people know more about malfeasance and greed in the drug industry than investigative journalist Gerald Posner, who literally wrote the book on it —Pharma: Greed, Lies, and the Poisoning Of America.\n“Most of the time I agree with your take,” he tells me. “FDA red tape bureaucracy is slow and costly and good R&D can cost a fortune, all with no guarantee of success. So risk takers, i.e. drug companies, should be rewarded with financial incentives.”\nBut, he adds, U.S. drug companies are already getting plenty of help. The U.S. has the longest patent protections of any major economy. He adds that big U.S. pharma companies get huge research support from taxpayers through the National Institute for Health.\n“From 2010 through 2016, every one of the 210 drugs approved for sale by the FDA were completely or in part funded by the NIH,” he says. The fund came to more than $100 billion, he adds.\nAll good points. But I fear that as long as it’s more profitable to invest in cigarettes or booze than it is in curing Alzheimer’s, we will all be left with Plan B for our old age: Hoping and praying we don’t get Alzheimer’s.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":1173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114285077,"gmtCreate":1623075562299,"gmtModify":1704195586679,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114285077","repostId":"1126396501","repostType":4,"isVote":1,"tweetType":1,"viewCount":767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114067750,"gmtCreate":1623036984970,"gmtModify":1704194776640,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Not bad","listText":"Not bad","text":"Not bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114067750","repostId":"1144781953","repostType":4,"repost":{"id":"1144781953","kind":"news","pubTimestamp":1623029453,"share":"https://ttm.financial/m/news/1144781953?lang=en_US&edition=fundamental","pubTime":"2021-06-07 09:30","market":"fut","language":"en","title":"WTI Oil Tops $70 for First Time Since 2018 as Market Tightens","url":"https://stock-news.laohu8.com/highlight/detail?id=1144781953","media":"Bloomberg","summary":"(Bloomberg) -- Oil in New York topped $70 a barrel for the first time since October 2018 as upbeat c","content":"<p>(Bloomberg) -- Oil in New York topped $70 a barrel for the first time since October 2018 as upbeat comments on the market from major trader Vitol Group added to optimism over the global demand recovery.</p><p>Futures rose as much as 0.6% after posting a second weekly gain, while global Brent traded above $72 a barrel. OPEC+ appears in control of crude prices, with U.S. production lagging pre-pandemic levels, Mike Muller, Vitol’s head of Asia, said at a conference on Sunday. The alliance is returning supply after output cuts helped to tighten the market.</p><p>A robust rebound from the virus in the U.S., China and Europe has driven prices more than 40% higher this year, although the Covid-19 comeback in Asia is a reminder that the recovery will be uneven. Russia’s Rosneft PJSC, meanwhile, warned of an impending shortfall in supply as global producers increasingly channel funds into a “hasty” energy transition.</p><p>“I expect crude oil to continue to push higher,” said Daniel Hynes, senior commodities strategist at Australia and New Zealand Banking Group Ltd. “The focus remains on demand, with traffic data suggesting the summer driving season should be positive.”</p><p>The market has firmed in a bullish structure. The prompt timespread for Brent is 41 cents in backwardation -- where near-dated prices are more expensive than later-dated ones. That compares with 37 cents a week earlier.</p><p>The decline in U.S. drilling and output makes OPEC+’s job of managing markets easier, Vitol’s Muller said at an event hosted by consultant Gulf Intelligence. Given delays in talks between Tehran and world powers on reviving a nuclear deal, it’s less likely more Iranian crude supply will hit the market before the fourth quarter, he added.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WTI Oil Tops $70 for First Time Since 2018 as Market Tightens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWTI Oil Tops $70 for First Time Since 2018 as Market Tightens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 09:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oil-steady-near-2018-high-230212928.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Oil in New York topped $70 a barrel for the first time since October 2018 as upbeat comments on the market from major trader Vitol Group added to optimism over the global demand ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oil-steady-near-2018-high-230212928.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-steady-near-2018-high-230212928.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144781953","content_text":"(Bloomberg) -- Oil in New York topped $70 a barrel for the first time since October 2018 as upbeat comments on the market from major trader Vitol Group added to optimism over the global demand recovery.Futures rose as much as 0.6% after posting a second weekly gain, while global Brent traded above $72 a barrel. OPEC+ appears in control of crude prices, with U.S. production lagging pre-pandemic levels, Mike Muller, Vitol’s head of Asia, said at a conference on Sunday. The alliance is returning supply after output cuts helped to tighten the market.A robust rebound from the virus in the U.S., China and Europe has driven prices more than 40% higher this year, although the Covid-19 comeback in Asia is a reminder that the recovery will be uneven. Russia’s Rosneft PJSC, meanwhile, warned of an impending shortfall in supply as global producers increasingly channel funds into a “hasty” energy transition.“I expect crude oil to continue to push higher,” said Daniel Hynes, senior commodities strategist at Australia and New Zealand Banking Group Ltd. “The focus remains on demand, with traffic data suggesting the summer driving season should be positive.”The market has firmed in a bullish structure. The prompt timespread for Brent is 41 cents in backwardation -- where near-dated prices are more expensive than later-dated ones. That compares with 37 cents a week earlier.The decline in U.S. drilling and output makes OPEC+’s job of managing markets easier, Vitol’s Muller said at an event hosted by consultant Gulf Intelligence. Given delays in talks between Tehran and world powers on reviving a nuclear deal, it’s less likely more Iranian crude supply will hit the market before the fourth quarter, he added.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1070,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114067997,"gmtCreate":1623036925419,"gmtModify":1704194775511,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582279635767115","idStr":"3582279635767115"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114067997","repostId":"1143555139","repostType":4,"isVote":1,"tweetType":1,"viewCount":995,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":117542129,"gmtCreate":1623154023161,"gmtModify":1704197167352,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Please like and comment for me","listText":"Please like and comment for me","text":"Please like and comment for me","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/117542129","repostId":"1154765176","repostType":4,"isVote":1,"tweetType":1,"viewCount":1212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185221565,"gmtCreate":1623654921057,"gmtModify":1704207913531,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Pls comment and like with many thanks","listText":"Pls comment and like with many thanks","text":"Pls comment and like with many thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/185221565","repostId":"1146430910","repostType":4,"repost":{"id":"1146430910","kind":"news","pubTimestamp":1623624483,"share":"https://ttm.financial/m/news/1146430910?lang=en_US&edition=fundamental","pubTime":"2021-06-14 06:48","market":"us","language":"en","title":"Oracle, Adobe, Kroger, General Motors, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1146430910","media":"Barrons","summary":"It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and","content":"<p>It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and Kroger on&nbsp;Thursday make up&nbsp;the notable reports over the coming days.</p>\n<p>Several other companies will speak with investors this week.&nbsp;Activision Blizzard and General Motors host their annual shareholder meetings on Monday, followed by Humana’s investor day on Tuesday and events by&nbsp;DXC Technology and NRG Energy on Thursday.</p>\n<p>The main event on the economic calendar this week will be the&nbsp;Federal Reserve’s rate-setting committee’s June meeting on Tuesday and Wednesday. The committee’s monetary-policy decision and a post-meeting press conference with Chairman&nbsp;Jerome Powell will be the focus of attention on Wednesday afternoon. Talk of inflation and bond-purchase tapering will be on the agenda.</p>\n<p>Data out this week include the Bureau of Labor Statistics’ producer price index for May and the Census Bureau’s retail-sales data for May, both on Tuesday, followed by the Conference Board’s Leading Economic Index for May on Thursday. There will also be data on the U.S. housing market out on Tuesday and Wednesday.</p>\n<p><b>Monday 6/14</b></p>\n<p>Roche Holding&nbsp;presents data on its spinal muscular atrophy drug, Evrysdi, at the 2021 CureSMA annual meeting.</p>\n<p>Activision Blizzard and General Motors hold their annual shareholder meetings.</p>\n<p><b>Tuesday 6/15</b></p>\n<p>Oracle announces fiscal fourth-quarter and full-year 2021 results.</p>\n<p>Humana hosts its biennial investor day virtually.</p>\n<p><b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for June. Economists forecast an 83 reading, matching the May figure. Home builders remain very bullish on the housing market but are concerned about the availability and cost of building materials.</p>\n<p><b>The Census Bureau</b>&nbsp;reports retail-sales data for May. Expectations are for a 0.5% month-over-month decline, following a flat April. Excluding autos, spending is seen rising 0.6%, compared with a 0.8% decrease previously.</p>\n<p><b>The Bureau of Labor</b>&nbsp;Statistics releases the producer price index for May. Consensus estimate is for a 0.4% monthly increase, with the core PPI, which excludes volatile food and energy prices, expected to rise 0.4% as well. This compares with gains of 0.6% and 0.7%, respectively, in April.</p>\n<p><b>Wednesday 6/16</b></p>\n<p><b>The FOMC announces</b>&nbsp;its monetary-policy decision. With the federal-funds rate all but certain to remain near zero, Wall Street is looking for clues as to when the Federal Reserve might scale back its bond purchases.</p>\n<p>Lennar reports quarterly results.</p>\n<p><b>The Census Bureau</b>&nbsp;reports new residential construction data for May. The economists forecast a seasonally adjusted annual rate of 1.63 million housing starts, slightly higher than April’s data. Housing starts are just below their post-financial-crisis peak of 1.73 million from March.</p>\n<p><b>Thursday 6/17</b></p>\n<p>Adobe and Kroger hold conference calls to discuss earnings.</p>\n<p>DXC Technology and NRG Energy hold their 2021 investor days.</p>\n<p><b>The Conference Board</b>&nbsp;releases its Leading Economic Index for May. The LEI is expected to rise 1.1% month over month to 114.5, after gaining 1.6% in April. The index has now surpassed its pre-Covid peak, set back in January of 2020. The Conference Board now projects 8% to 9% annualized gross-domestic-product growth for the second quarter, and 6.4% for the year.</p>\n<p><b>The Department of Labor</b>&nbsp;reports initial jobless claims for the week ending on June 15. Jobless claims this past week were 376,000, the lowest total since March of 2020.</p>\n<p><b>Friday 6/18</b></p>\n<p><b>The Bank of Japan</b>&nbsp;announces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at negative 0.1%. The BOJ recently updated its GDP forecast to 4% growth for fiscal 2021 and 2.4% for fiscal 2022.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oracle, Adobe, Kroger, General Motors, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOracle, Adobe, Kroger, General Motors, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 06:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/oracle-adobe-kroger-general-motors-and-other-stocks-for-investors-to-watch-this-week-51623610821?mod=hp_LEADSUPP_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and Kroger on Thursday make up the notable reports over the coming days.\nSeveral other companies will ...</p>\n\n<a href=\"https://www.barrons.com/articles/oracle-adobe-kroger-general-motors-and-other-stocks-for-investors-to-watch-this-week-51623610821?mod=hp_LEADSUPP_2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","GM":"通用汽车",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","KR":"克罗格","ADBE":"Adobe","ORCL":"甲骨文"},"source_url":"https://www.barrons.com/articles/oracle-adobe-kroger-general-motors-and-other-stocks-for-investors-to-watch-this-week-51623610821?mod=hp_LEADSUPP_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146430910","content_text":"It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and Kroger on Thursday make up the notable reports over the coming days.\nSeveral other companies will speak with investors this week. Activision Blizzard and General Motors host their annual shareholder meetings on Monday, followed by Humana’s investor day on Tuesday and events by DXC Technology and NRG Energy on Thursday.\nThe main event on the economic calendar this week will be the Federal Reserve’s rate-setting committee’s June meeting on Tuesday and Wednesday. The committee’s monetary-policy decision and a post-meeting press conference with Chairman Jerome Powell will be the focus of attention on Wednesday afternoon. Talk of inflation and bond-purchase tapering will be on the agenda.\nData out this week include the Bureau of Labor Statistics’ producer price index for May and the Census Bureau’s retail-sales data for May, both on Tuesday, followed by the Conference Board’s Leading Economic Index for May on Thursday. There will also be data on the U.S. housing market out on Tuesday and Wednesday.\nMonday 6/14\nRoche Holding presents data on its spinal muscular atrophy drug, Evrysdi, at the 2021 CureSMA annual meeting.\nActivision Blizzard and General Motors hold their annual shareholder meetings.\nTuesday 6/15\nOracle announces fiscal fourth-quarter and full-year 2021 results.\nHumana hosts its biennial investor day virtually.\nThe National Association of Home Builders releases its Housing Market Index for June. Economists forecast an 83 reading, matching the May figure. Home builders remain very bullish on the housing market but are concerned about the availability and cost of building materials.\nThe Census Bureau reports retail-sales data for May. Expectations are for a 0.5% month-over-month decline, following a flat April. Excluding autos, spending is seen rising 0.6%, compared with a 0.8% decrease previously.\nThe Bureau of Labor Statistics releases the producer price index for May. Consensus estimate is for a 0.4% monthly increase, with the core PPI, which excludes volatile food and energy prices, expected to rise 0.4% as well. This compares with gains of 0.6% and 0.7%, respectively, in April.\nWednesday 6/16\nThe FOMC announces its monetary-policy decision. With the federal-funds rate all but certain to remain near zero, Wall Street is looking for clues as to when the Federal Reserve might scale back its bond purchases.\nLennar reports quarterly results.\nThe Census Bureau reports new residential construction data for May. The economists forecast a seasonally adjusted annual rate of 1.63 million housing starts, slightly higher than April’s data. Housing starts are just below their post-financial-crisis peak of 1.73 million from March.\nThursday 6/17\nAdobe and Kroger hold conference calls to discuss earnings.\nDXC Technology and NRG Energy hold their 2021 investor days.\nThe Conference Board releases its Leading Economic Index for May. The LEI is expected to rise 1.1% month over month to 114.5, after gaining 1.6% in April. The index has now surpassed its pre-Covid peak, set back in January of 2020. The Conference Board now projects 8% to 9% annualized gross-domestic-product growth for the second quarter, and 6.4% for the year.\nThe Department of Labor reports initial jobless claims for the week ending on June 15. Jobless claims this past week were 376,000, the lowest total since March of 2020.\nFriday 6/18\nThe Bank of Japan announces its monetary-policy decision. The central bank is widely expected to keep its key interest rate at negative 0.1%. The BOJ recently updated its GDP forecast to 4% growth for fiscal 2021 and 2.4% for fiscal 2022.","news_type":1,"symbols_score_info":{"KR":0.9,".DJI":0.9,".SPX":0.9,"ORCL":0.9,"GM":0.9,"ADBE":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":3508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120825133,"gmtCreate":1624319468622,"gmtModify":1703833212883,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/120825133","repostId":"1167650307","repostType":4,"isVote":1,"tweetType":1,"viewCount":3138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188293635,"gmtCreate":1623441824927,"gmtModify":1704203786171,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188293635","repostId":"2142572209","repostType":4,"isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":115280689,"gmtCreate":1623000672641,"gmtModify":1704194211730,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Yea","listText":"Yea","text":"Yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/115280689","repostId":"1156802172","repostType":4,"repost":{"id":"1156802172","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1622950106,"share":"https://ttm.financial/m/news/1156802172?lang=en_US&edition=fundamental","pubTime":"2021-06-06 11:28","market":"us","language":"en","title":"Nio Begins Prepping For Nio Day 2021: What We Know So Far","url":"https://stock-news.laohu8.com/highlight/detail?id=1156802172","media":"Benzinga","summary":"The catalyst that drove NIO Inc. shares to an all-time high of $66.99 earlier this year was Nio Day ","content":"<p>The catalyst that drove&nbsp;<b>NIO Inc.</b>&nbsp;shares to an all-time high of $66.99 earlier this year was Nio Day 2020&nbsp;on Jan. 9. The stock has pulled back since then and is currently trading roughly 40% off the highs.</p>\n<p>Against this backdrop, it has emerged that&nbsp;the company has started laying the groundwork for the next Nio Day.</p>\n<p><b>What Happened:</b>Nio posted on its Nio App that cities can now start bidding for hosting Nio Day 2021, a Nio spokesperson confirmed to Benzinga.</p>\n<p>The bidding process as&nbsp;explained&nbsp;by CnEVPost is as follows:</p>\n<p>The applications on behalf of the host city should be submitted by local Nio Clubs, and if a city has more than one Nio Club, a joint bid can be made.</p>\n<p>Nio mandates&nbsp;a potential&nbsp;host city should not have hosted Nio Day in the past eight years.</p>\n<p>The city should have an indoor venue with a seating capacity of more than&nbsp;8,000 and&nbsp;available for hosting 10&nbsp;consecutive days sometime between Dec. 1, 2021&nbsp;and Jan. 15, 2022.</p>\n<p>The company has provided a time window of June 4 through June 8 for submitting an intent to apply. After conducting preliminary surveys in shortlisted cities from June 9 to June 15, Nio will start receiving applications.</p>\n<p>Following the evaluation of applications, the company will shortlist three cities on July 3 and present the list on the Nio App, allowing Nio users to vote July 23 and 24. The final winner will be decided based on the votes.</p>\n<p><b>Why It's Important:</b>Nio Day is an annual event for Nio users and other guests.&nbsp;The company has been hosting the event since 2017&nbsp;when the first Nio Day was in Beijing, where its first mass-produced model, the ES8, debuted.</p>\n<p>Nio Day 2020&nbsp;was held in Chengdu on Jan. 9, 2021. The annual event meant for 2020 was pushed to early 2021 due to the COVID-19 pandemic. The company unveiled its first-ever sedan, named ET7, at the event. It also made product and service-related announcements.</p>\n<p>Several rumors have surfaced regarding a mass-market model from Nio under a different brand name. The company could shed some light on this at Nio Day 2021 event.</p>\n<p>With the ET7 scheduled to be made available commercially in the first quarter of 2022, the company could share more details on the sedan and its launch plans.</p>\n<p>Nio users may also look ahead to more details on the company's recent&nbsp;expansion into Norway.</p>\n<p>At last check Friday at publication, Nio shares were rallying 2.54% to $41.94.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Begins Prepping For Nio Day 2021: What We Know So Far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Begins Prepping For Nio Day 2021: What We Know So Far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-06 11:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>The catalyst that drove&nbsp;<b>NIO Inc.</b>&nbsp;shares to an all-time high of $66.99 earlier this year was Nio Day 2020&nbsp;on Jan. 9. The stock has pulled back since then and is currently trading roughly 40% off the highs.</p>\n<p>Against this backdrop, it has emerged that&nbsp;the company has started laying the groundwork for the next Nio Day.</p>\n<p><b>What Happened:</b>Nio posted on its Nio App that cities can now start bidding for hosting Nio Day 2021, a Nio spokesperson confirmed to Benzinga.</p>\n<p>The bidding process as&nbsp;explained&nbsp;by CnEVPost is as follows:</p>\n<p>The applications on behalf of the host city should be submitted by local Nio Clubs, and if a city has more than one Nio Club, a joint bid can be made.</p>\n<p>Nio mandates&nbsp;a potential&nbsp;host city should not have hosted Nio Day in the past eight years.</p>\n<p>The city should have an indoor venue with a seating capacity of more than&nbsp;8,000 and&nbsp;available for hosting 10&nbsp;consecutive days sometime between Dec. 1, 2021&nbsp;and Jan. 15, 2022.</p>\n<p>The company has provided a time window of June 4 through June 8 for submitting an intent to apply. After conducting preliminary surveys in shortlisted cities from June 9 to June 15, Nio will start receiving applications.</p>\n<p>Following the evaluation of applications, the company will shortlist three cities on July 3 and present the list on the Nio App, allowing Nio users to vote July 23 and 24. The final winner will be decided based on the votes.</p>\n<p><b>Why It's Important:</b>Nio Day is an annual event for Nio users and other guests.&nbsp;The company has been hosting the event since 2017&nbsp;when the first Nio Day was in Beijing, where its first mass-produced model, the ES8, debuted.</p>\n<p>Nio Day 2020&nbsp;was held in Chengdu on Jan. 9, 2021. The annual event meant for 2020 was pushed to early 2021 due to the COVID-19 pandemic. The company unveiled its first-ever sedan, named ET7, at the event. It also made product and service-related announcements.</p>\n<p>Several rumors have surfaced regarding a mass-market model from Nio under a different brand name. The company could shed some light on this at Nio Day 2021 event.</p>\n<p>With the ET7 scheduled to be made available commercially in the first quarter of 2022, the company could share more details on the sedan and its launch plans.</p>\n<p>Nio users may also look ahead to more details on the company's recent&nbsp;expansion into Norway.</p>\n<p>At last check Friday at publication, Nio shares were rallying 2.54% to $41.94.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156802172","content_text":"The catalyst that drove NIO Inc. shares to an all-time high of $66.99 earlier this year was Nio Day 2020 on Jan. 9. The stock has pulled back since then and is currently trading roughly 40% off the highs.\nAgainst this backdrop, it has emerged that the company has started laying the groundwork for the next Nio Day.\nWhat Happened:Nio posted on its Nio App that cities can now start bidding for hosting Nio Day 2021, a Nio spokesperson confirmed to Benzinga.\nThe bidding process as explained by CnEVPost is as follows:\nThe applications on behalf of the host city should be submitted by local Nio Clubs, and if a city has more than one Nio Club, a joint bid can be made.\nNio mandates a potential host city should not have hosted Nio Day in the past eight years.\nThe city should have an indoor venue with a seating capacity of more than 8,000 and available for hosting 10 consecutive days sometime between Dec. 1, 2021 and Jan. 15, 2022.\nThe company has provided a time window of June 4 through June 8 for submitting an intent to apply. After conducting preliminary surveys in shortlisted cities from June 9 to June 15, Nio will start receiving applications.\nFollowing the evaluation of applications, the company will shortlist three cities on July 3 and present the list on the Nio App, allowing Nio users to vote July 23 and 24. The final winner will be decided based on the votes.\nWhy It's Important:Nio Day is an annual event for Nio users and other guests. The company has been hosting the event since 2017 when the first Nio Day was in Beijing, where its first mass-produced model, the ES8, debuted.\nNio Day 2020 was held in Chengdu on Jan. 9, 2021. The annual event meant for 2020 was pushed to early 2021 due to the COVID-19 pandemic. The company unveiled its first-ever sedan, named ET7, at the event. It also made product and service-related announcements.\nSeveral rumors have surfaced regarding a mass-market model from Nio under a different brand name. The company could shed some light on this at Nio Day 2021 event.\nWith the ET7 scheduled to be made available commercially in the first quarter of 2022, the company could share more details on the sedan and its launch plans.\nNio users may also look ahead to more details on the company's recent expansion into Norway.\nAt last check Friday at publication, Nio shares were rallying 2.54% to $41.94.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129947356,"gmtCreate":1624354790375,"gmtModify":1703834229415,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Like and comment.&nbsp; Thank you","listText":"Like and comment.&nbsp; Thank you","text":"Like and comment. Thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129947356","repostId":"1186919064","repostType":4,"isVote":1,"tweetType":1,"viewCount":3122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161037621,"gmtCreate":1623896069063,"gmtModify":1703822870601,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Like and comment pls. Thanks ?","listText":"Like and comment pls. Thanks ?","text":"Like and comment pls. Thanks ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161037621","repostId":"2144130887","repostType":4,"isVote":1,"tweetType":1,"viewCount":2978,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117543634,"gmtCreate":1623153771328,"gmtModify":1704197161475,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/117543634","repostId":"1127979401","repostType":4,"repost":{"id":"1127979401","kind":"news","pubTimestamp":1623153568,"share":"https://ttm.financial/m/news/1127979401?lang=en_US&edition=fundamental","pubTime":"2021-06-08 19:59","market":"us","language":"en","title":"Opinion: Only ‘greedy’ drug companies will cure Alzheimer’s","url":"https://stock-news.laohu8.com/highlight/detail?id=1127979401","media":"marketwatch","summary":"Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my ","content":"<p><img src=\"https://static.tigerbbs.com/783580e857537ceb68ca7c6330ee4132\" tg-width=\"1260\" tg-height=\"736\">Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my fellow members of the (ahem) “mainstream media.”</p>\n<p>Now that BiogenBIIB,+38.34%has got approval forits new Alzheimer’s drug—the first approved by the FDA in almost 20 years — how much should they be allowed to charge for it?</p>\n<p>What’s the ethically correct figure? What will exempt them from charges of “greed” or “gouging?” What is “too much?”</p>\n<p>The manufacturing cost per pill? The cost plus a small margin? What’s the number?</p>\n<p>I bring this up because few things matter as much for the lives of senior citizens in America—and seniors in the rest of the world—than the development of new drugs. I have personally seen up close how Alzheimer’s destroys people, sometimes as young as their 50s and 60s. This has included close members of my family.</p>\n<p>Some six million Americans already have this cruel, vicious and incurable disease, and ahorrific 50 million around the world. That’s 50 million death sentences. Ten million more get it every year.</p>\n<p>The drug industry developed five vaccines in one year for COVID-19, a disease associated with the deaths of 3.7 million people world-wide. Alzheimer’s treatments? Oh, one for every 20 years.</p>\n<p>Let’s be honest: Many people subconsciously shrug off this issue on the principle that Alzheimer’s will only happen to someone else. Alas, many of the people reading this article are going to get this disease. For many more, your father, mother, wife or husband will get it. Or a sibling or close friend. At which point, the “hey, maybe we should have made this a bigger national priority” argument will strike, but too late to help.</p>\n<p>This is the context worth bearing in mind when we hear about drugs getting approved—and, just as importantly, when we hear people demagoguing about “greedy” drug companies and “overpriced” drugs. It’s not just this new Alzheimer’s drug, either.</p>\n<p>If “drug” companies are making out like bandits, someone really has to explain to me why it doesn’t show up in the…er…stock prices. In the past decade, investors the iShares U.S. Pharmaceuticals exchange-traded fundIHE,+0.61%have made far lower returns than they could have done just by randomly picking a bunch of non-pharmaceutical stocks out of the newspaper. These companies have been worse investments than a simple S&amp;P 500SPX,-0.08%index fund like the SPDR S&amp;P 500 ETFSPY,-0.10%,or the Invesco S&amp;P 500 Equal Weight ETFRSP,-0.18%.</p>\n<p>Even Biogen itself had substantially underperformed the broader stock market index for a decade. Until Monday.</p>\n<p>No, the industry returns aren’t terrible. But they are hardly the giant free oil well that critics sometimes suggest. I checked out the data from Dartmouth College finance professor Kenneth French, who has tracked stock market returns by industry going back decades. Going all the way back to the 1920s, according to his numbers, the pharmaceuticals industry barely cracks the top one-third of all industries by stock returns. So far this millennium, the total returns from major pharmaceutical companies have been about a third less than those from the S&amp;P 500 index. Biotechs have done much better, but they were a much smaller sector. And even biotech has trailed the returns of alcohol and tobacco companies.</p>\n<p>How are we going to get billions of dollars more capital invested in curing Alzheimer’s and diabetes and cancer when investors can make more money investing in making booze and cigarettes? This is upside down.</p>\n<p>Meanwhile the regulation are all messed up and back to front as well.This headline says it all: “FDA Approves Alzheimer’s Drug Despite Fierce Debate Over&nbsp;Whether&nbsp;It Works.”</p>\n<p>This is nuts. Maybe the new treatment makes things better, maybe it doesn’t. Apparently people aren’t certain. It’s hardly a surprise: The treatment is new, and the disease is complicated. But the first question to ask isn’t whether it makes things better, but whether it makes things worse. The current situation is catastrophic for anyone with the disease. People are dying. Lives are being destroyed.</p>\n<p>Waiting to be sure treatment works would be like falling out of a plane with a parachute on, but hesitating to pull the cord because, well, it might not work. It suggests a basic misunderstanding of game theory. (Or common sense.)</p>\n<p>It’s one thing to hesitate about approving a new drug for a nonfatal illness. You don’t want to make people sicker, or cause needless suffering or death. But with this kind of illness that really doesn’t apply.</p>\n<p>Anyone who says “oh, no, we need to be really careful, and if need be delay these new treatments for years to make sure they are absolutely 100% safe” is speaking from a position of privilege. They should try saying that to someone watching a loved one be destroyed by the illness. It’s easy to play that card when it’s not happening to you, or someone you love.</p>\n<p>A look through the Biogen’s public filings tells the sorry story. This new&nbsp;Alzheimer’s&nbsp;treatment entered Phase 3 trials in 2015—six years ago. Did I mention it took one year to get COVID vaccines to market?</p>\n<p>Meanwhile, check out all the costs associated with developing this treatment. Biogen struck a collaboration deal with Eisai to work on this drug in 2014. Since then the two of them have spent a total of $1.1 billion on it. If it hadn’t been approved, that’s $1.1 billion down the drain.</p>\n<p>I want more of these treatments. And I want them quickly, not every two decades. I want trillions pouring into this industry. And I know that lower returns, and more bureaucracy, aren’t the way to get them.</p>\n<p>None of this, of course, means blind, passive or foolish naiveté about the drug industry or pricing. Drug manufacturers spend about $160 million a year on lobbying, and people involved in the business donated nearly $30 million a year to politicians running for office. Look through the proxy statements and you’ll see plenty of Big Pharma CEOs living off<i>the fatta the lan</i>(like lots of other CEOs).Yes, of course Medicare should have greater freedom to negotiate drug prices.</p>\n<p>Few people know more about malfeasance and greed in the drug industry than investigative journalist Gerald Posner, who literally wrote the book on it —Pharma: Greed, Lies, and the Poisoning Of America.</p>\n<p>“Most of the time I agree with your take,” he tells me. “FDA red tape bureaucracy is slow and costly and good R&amp;D can cost a fortune, all with no guarantee of success. So risk takers, i.e. drug companies, should be rewarded with financial incentives.”</p>\n<p>But, he adds, U.S. drug companies are already getting plenty of help. The U.S. has the longest patent protections of any major economy. He adds that big U.S. pharma companies get huge research support from taxpayers through the National Institute for Health.</p>\n<p>“From 2010 through 2016, every one of the 210 drugs approved for sale by the FDA were completely or in part funded by the NIH,” he says. The fund came to more than $100 billion, he adds.</p>\n<p>All good points. But I fear that as long as it’s more profitable to invest in cigarettes or booze than it is in curing Alzheimer’s, we will all be left with Plan B for our old age: Hoping and praying we don’t get Alzheimer’s.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opinion: Only ‘greedy’ drug companies will cure Alzheimer’s</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpinion: Only ‘greedy’ drug companies will cure Alzheimer’s\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/only-greedy-drug-companies-will-cure-alzheimers-11623152892?mod=newsviewer_click><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my fellow members of the (ahem) “mainstream media.”\nNow that BiogenBIIB,+38.34%has got approval forits ...</p>\n\n<a href=\"https://www.marketwatch.com/story/only-greedy-drug-companies-will-cure-alzheimers-11623152892?mod=newsviewer_click\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.marketwatch.com/story/only-greedy-drug-companies-will-cure-alzheimers-11623152892?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1127979401","content_text":"Here’s a question for everyone in Congress and the White House, the federal bureaucracy, and all my fellow members of the (ahem) “mainstream media.”\nNow that BiogenBIIB,+38.34%has got approval forits new Alzheimer’s drug—the first approved by the FDA in almost 20 years — how much should they be allowed to charge for it?\nWhat’s the ethically correct figure? What will exempt them from charges of “greed” or “gouging?” What is “too much?”\nThe manufacturing cost per pill? The cost plus a small margin? What’s the number?\nI bring this up because few things matter as much for the lives of senior citizens in America—and seniors in the rest of the world—than the development of new drugs. I have personally seen up close how Alzheimer’s destroys people, sometimes as young as their 50s and 60s. This has included close members of my family.\nSome six million Americans already have this cruel, vicious and incurable disease, and ahorrific 50 million around the world. That’s 50 million death sentences. Ten million more get it every year.\nThe drug industry developed five vaccines in one year for COVID-19, a disease associated with the deaths of 3.7 million people world-wide. Alzheimer’s treatments? Oh, one for every 20 years.\nLet’s be honest: Many people subconsciously shrug off this issue on the principle that Alzheimer’s will only happen to someone else. Alas, many of the people reading this article are going to get this disease. For many more, your father, mother, wife or husband will get it. Or a sibling or close friend. At which point, the “hey, maybe we should have made this a bigger national priority” argument will strike, but too late to help.\nThis is the context worth bearing in mind when we hear about drugs getting approved—and, just as importantly, when we hear people demagoguing about “greedy” drug companies and “overpriced” drugs. It’s not just this new Alzheimer’s drug, either.\nIf “drug” companies are making out like bandits, someone really has to explain to me why it doesn’t show up in the…er…stock prices. In the past decade, investors the iShares U.S. Pharmaceuticals exchange-traded fundIHE,+0.61%have made far lower returns than they could have done just by randomly picking a bunch of non-pharmaceutical stocks out of the newspaper. These companies have been worse investments than a simple S&P 500SPX,-0.08%index fund like the SPDR S&P 500 ETFSPY,-0.10%,or the Invesco S&P 500 Equal Weight ETFRSP,-0.18%.\nEven Biogen itself had substantially underperformed the broader stock market index for a decade. Until Monday.\nNo, the industry returns aren’t terrible. But they are hardly the giant free oil well that critics sometimes suggest. I checked out the data from Dartmouth College finance professor Kenneth French, who has tracked stock market returns by industry going back decades. Going all the way back to the 1920s, according to his numbers, the pharmaceuticals industry barely cracks the top one-third of all industries by stock returns. So far this millennium, the total returns from major pharmaceutical companies have been about a third less than those from the S&P 500 index. Biotechs have done much better, but they were a much smaller sector. And even biotech has trailed the returns of alcohol and tobacco companies.\nHow are we going to get billions of dollars more capital invested in curing Alzheimer’s and diabetes and cancer when investors can make more money investing in making booze and cigarettes? This is upside down.\nMeanwhile the regulation are all messed up and back to front as well.This headline says it all: “FDA Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works.”\nThis is nuts. Maybe the new treatment makes things better, maybe it doesn’t. Apparently people aren’t certain. It’s hardly a surprise: The treatment is new, and the disease is complicated. But the first question to ask isn’t whether it makes things better, but whether it makes things worse. The current situation is catastrophic for anyone with the disease. People are dying. Lives are being destroyed.\nWaiting to be sure treatment works would be like falling out of a plane with a parachute on, but hesitating to pull the cord because, well, it might not work. It suggests a basic misunderstanding of game theory. (Or common sense.)\nIt’s one thing to hesitate about approving a new drug for a nonfatal illness. You don’t want to make people sicker, or cause needless suffering or death. But with this kind of illness that really doesn’t apply.\nAnyone who says “oh, no, we need to be really careful, and if need be delay these new treatments for years to make sure they are absolutely 100% safe” is speaking from a position of privilege. They should try saying that to someone watching a loved one be destroyed by the illness. It’s easy to play that card when it’s not happening to you, or someone you love.\nA look through the Biogen’s public filings tells the sorry story. This new Alzheimer’s treatment entered Phase 3 trials in 2015—six years ago. Did I mention it took one year to get COVID vaccines to market?\nMeanwhile, check out all the costs associated with developing this treatment. Biogen struck a collaboration deal with Eisai to work on this drug in 2014. Since then the two of them have spent a total of $1.1 billion on it. If it hadn’t been approved, that’s $1.1 billion down the drain.\nI want more of these treatments. And I want them quickly, not every two decades. I want trillions pouring into this industry. And I know that lower returns, and more bureaucracy, aren’t the way to get them.\nNone of this, of course, means blind, passive or foolish naiveté about the drug industry or pricing. Drug manufacturers spend about $160 million a year on lobbying, and people involved in the business donated nearly $30 million a year to politicians running for office. Look through the proxy statements and you’ll see plenty of Big Pharma CEOs living offthe fatta the lan(like lots of other CEOs).Yes, of course Medicare should have greater freedom to negotiate drug prices.\nFew people know more about malfeasance and greed in the drug industry than investigative journalist Gerald Posner, who literally wrote the book on it —Pharma: Greed, Lies, and the Poisoning Of America.\n“Most of the time I agree with your take,” he tells me. “FDA red tape bureaucracy is slow and costly and good R&D can cost a fortune, all with no guarantee of success. So risk takers, i.e. drug companies, should be rewarded with financial incentives.”\nBut, he adds, U.S. drug companies are already getting plenty of help. The U.S. has the longest patent protections of any major economy. He adds that big U.S. pharma companies get huge research support from taxpayers through the National Institute for Health.\n“From 2010 through 2016, every one of the 210 drugs approved for sale by the FDA were completely or in part funded by the NIH,” he says. The fund came to more than $100 billion, he adds.\nAll good points. But I fear that as long as it’s more profitable to invest in cigarettes or booze than it is in curing Alzheimer’s, we will all be left with Plan B for our old age: Hoping and praying we don’t get Alzheimer’s.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":1173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114067997,"gmtCreate":1623036925419,"gmtModify":1704194775511,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114067997","repostId":"1143555139","repostType":4,"isVote":1,"tweetType":1,"viewCount":995,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114065742,"gmtCreate":1623036881786,"gmtModify":1704194773573,"author":{"id":"3582279635767115","authorId":"3582279635767115","name":"xiaoniu2021","avatar":"https://static.tigerbbs.com/2b48490ff89e888e7ae9323ab94ce117","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582279635767115","authorIdStr":"3582279635767115"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114065742","repostId":"2141926289","repostType":4,"isVote":1,"tweetType":1,"viewCount":652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}